Bone Properties in Hypoparathyroidism: Effects of PTH
Primary Purpose
Hypoparathyroidism
Status
Completed
Phase
Phase 2
Locations
United States
Study Type
Interventional
Intervention
PTH
Sponsored by
About this trial
This is an interventional treatment trial for Hypoparathyroidism
Eligibility Criteria
Inclusion Criteria:
- Hypoparathyroidism
Exclusion Criteria:
- Bisphosphonate use
Sites / Locations
- Columbia University
Arms of the Study
Arm 1
Arm Type
Experimental
Arm Label
PTH(1-84)
Arm Description
100mcg of PTH1-84 every other day, every day, or every three days
Outcomes
Primary Outcome Measures
Requirements for Calcium Supplementation
Serum and urinary calcium levels maintained by change in requirements for calcium supplementation
Secondary Outcome Measures
Percent Change in BMD From Baseline to 24 Months by DXA
Bone Mineral Density (BMD) as measured by Dual-energy X-ray absorptiometry (DXA).
Trabecular Width
Trabecular width was obtained from histomorphometric assessment of percutaneous iliac crest bone biopsy. Trabecular width is the thickness of individual pieces of the spongy bone section. The structure and microscopic organization of a small piece of biopsied pelvic bone was analyzed.
Trabecular Number
trabecular number done on histomorphometric assessment of percutaneous iliac crest bone biopsy. Trabecular number is the number of individual pieces of the spongy bone section. The structure and microscopic organization of a small piece of biopsied pelvic bone was analyzed.
Cortical Porosity
Cortical porosity done on histomorphometric assessment of percutaneous iliac crest bone biopsy. Cortical Porosity measures how many tiny holes there are in the solid bone section. The structure and microscopic organization of a small piece of biopsied pelvic bone was analyzed.
Mineralizing Surface
Mineralizing surface done on histomorphometric assessment of percutaneous iliac crest bone biopsy. Mineralizing surface measures how much of bone is getting new mineral put on it. The structure and microscopic organization of a small piece of biopsied pelvic bone was analyzed.
Full Information
NCT ID
NCT00473265
First Posted
May 14, 2007
Last Updated
July 14, 2015
Sponsor
John P. Bilezikian
Collaborators
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
1. Study Identification
Unique Protocol Identification Number
NCT00473265
Brief Title
Bone Properties in Hypoparathyroidism: Effects of PTH
Official Title
Bone Properties in Hypoparathyroidism: Effects of PTH
Study Type
Interventional
2. Study Status
Record Verification Date
July 2015
Overall Recruitment Status
Completed
Study Start Date
May 2004 (undefined)
Primary Completion Date
January 2011 (Actual)
Study Completion Date
June 2014 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor-Investigator
Name of the Sponsor
John P. Bilezikian
Collaborators
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
Whereas much information is known about the properties of bone in primary hyperparathyroidism, a disorder of parathyroid hormone (PTH) excess, virtually nothing is known about the skeleton in hypoparathyroidism, a disorder in which PTH is absent. The purpose of this research project is to test the hypothesis that the skeleton in hypoparathyroidism is abnormal in its metabolic, densitometric, geometric, biomechanical and microarchitectural features. We will also test the hypothesis that the skeleton is dependent upon PTH for normal structure and function. Using non-invasive approaches as well as direct analysis of bone itself, the human hypoparathyroid skeleton will be thoroughly characterized. With each patient serving as his/her own control, we will determine how, to what extent, and in what ways the administration of PTH restores skeletal dynamics and structure to the hypoparathyroid skeleton. In this way, we will identify those structural and dynamic elements of the skeleton that are influenced by or dependent upon PTH. Methods to be utilized include dual energy X-ray absorptiometry, quantitative central and peripheral computed tomography, geometry and size quantification, histomorphometry by standard and microCT methods, finite element analysis, biochemical bone markers, quantitative back scattered electron imaging, and Fourier Transform Infrared Spectroscopy. This research project will extend our knowledge of the skeletal effects of PTH to its deficient range and thus complete our understanding of PTH action on bone gained by our many years of studying PTH overexpression in primary hyperparathyroidism. This investigation may also provide insight into the means by which PTH helps to restore the skeleton when it is used to treat osteoporosis.
Detailed Description
A detailed description of the methods used in this study include the following: direct analysis of bone itself. skeletal dynamics and structure such as dual energy X-ray absorptiometry, quantitative central and peripheral computed tomography, geometry and size quantification, histomorphometry by standard and microCT methods, finite element analysis, biochemical bone markers, quantitative back scattered electron imaging, and Fourier Transform Infrared Spectroscopy.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Hypoparathyroidism
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 2, Phase 3
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
68 (Actual)
8. Arms, Groups, and Interventions
Arm Title
PTH(1-84)
Arm Type
Experimental
Arm Description
100mcg of PTH1-84 every other day, every day, or every three days
Intervention Type
Drug
Intervention Name(s)
PTH
Other Intervention Name(s)
teriparatide, Preotact, PTH1-84, rhPTH, Natpara
Primary Outcome Measure Information:
Title
Requirements for Calcium Supplementation
Description
Serum and urinary calcium levels maintained by change in requirements for calcium supplementation
Time Frame
2 years
Secondary Outcome Measure Information:
Title
Percent Change in BMD From Baseline to 24 Months by DXA
Description
Bone Mineral Density (BMD) as measured by Dual-energy X-ray absorptiometry (DXA).
Time Frame
baseline versus 24 months
Title
Trabecular Width
Description
Trabecular width was obtained from histomorphometric assessment of percutaneous iliac crest bone biopsy. Trabecular width is the thickness of individual pieces of the spongy bone section. The structure and microscopic organization of a small piece of biopsied pelvic bone was analyzed.
Time Frame
baseline versus two years
Title
Trabecular Number
Description
trabecular number done on histomorphometric assessment of percutaneous iliac crest bone biopsy. Trabecular number is the number of individual pieces of the spongy bone section. The structure and microscopic organization of a small piece of biopsied pelvic bone was analyzed.
Time Frame
baseline versus two years
Title
Cortical Porosity
Description
Cortical porosity done on histomorphometric assessment of percutaneous iliac crest bone biopsy. Cortical Porosity measures how many tiny holes there are in the solid bone section. The structure and microscopic organization of a small piece of biopsied pelvic bone was analyzed.
Time Frame
baseline versus two years
Title
Mineralizing Surface
Description
Mineralizing surface done on histomorphometric assessment of percutaneous iliac crest bone biopsy. Mineralizing surface measures how much of bone is getting new mineral put on it. The structure and microscopic organization of a small piece of biopsied pelvic bone was analyzed.
Time Frame
baseline versus one year
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Hypoparathyroidism
Exclusion Criteria:
Bisphosphonate use
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
John P Bilezikian, MD
Organizational Affiliation
Columbia University
Official's Role
Principal Investigator
Facility Information:
Facility Name
Columbia University
City
New York
State/Province
New York
ZIP/Postal Code
10032
Country
United States
12. IPD Sharing Statement
Citations:
PubMed Identifier
29972871
Citation
Rubin MR, Zhou H, Cusano NE, Majeed R, Omeragic B, Gomez M, Nickolas TL, Dempster DW, Bilezikian JP. The Effects of Long-term Administration of rhPTH(1-84) in Hypoparathyroidism by Bone Histomorphometry. J Bone Miner Res. 2018 Nov;33(11):1931-1939. doi: 10.1002/jbmr.3543. Epub 2018 Aug 16.
Results Reference
derived
Learn more about this trial
Bone Properties in Hypoparathyroidism: Effects of PTH
We'll reach out to this number within 24 hrs